Research programme: SeV-based gene therapies - ID Pharma

Drug Profile

Research programme: SeV-based gene therapies - ID Pharma

Alternative Names: SeV 10102; SeV 10401; SeV 10501; SeV 20201; SeV 20202; SeV 20301; SeV 20302; SeV2 0401

Latest Information Update: 14 Dec 2015

Price : $50

At a glance

  • Originator DNAVEC Corporation
  • Class Gene therapies; Nucleic acids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Cystic fibrosis; Ischaemic heart disorders

Highest Development Phases

  • Preclinical Brain cancer; Cystic fibrosis; Ischaemic heart disorders; Malignant melanoma; Rheumatoid arthritis
  • No development reported Alzheimer's disease; Coronavirus infections; HIV-1 infections

Most Recent Events

  • 03 Feb 2011 No development reported - Preclinical for HIV-1 infections in Japan (unspecified route)
  • 03 Feb 2011 No development reported - Preclinical for Coronavirus infections in Japan (unspecified route)
  • 03 Feb 2011 No development reported - Preclinical for Alzheimer's disease in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top